Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, including Vykat XR, the first and only ...

In the announcement, FDA Commissioner Mackary said, “Bayesian methodologies help address two of the biggest problems of drug ...

Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain. Pharmacy ...

First-year discontinuation commonly reflects high out-of-pocket costs coupled with expectations that weight loss will be ...

In response, many employers and advisers have adopted alternative funding programs (AFPs) as a targeted way to manage ...

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...

Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why it’s common for patients to stop taking the medication.

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

Soley Therapeutics’ co-founder and CEO Yerem Yeghiazarians, MD, spoke with Pharmaceutical Executive about the unique approach ...

In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump ...